FORGED IN INDUSTRY.
BUILT FOR EMERGING BIOPHARMA.
Emerging biopharma doesn't get a second launch.
A boutique partner for VC and PE-backed biopharma. Clinical to commercial, market access, commercial operations, from launch through transformation. Senior practitioners in the room with you, hands on the work from first call to last decision.
OUR CONVICTION.
We build from the inside out.
Not adjacent to the work. Not advising someone else who is doing it. From global biopharmas to start-ups, we have been the people whose names were on the decisions.
We've been in your seat.
No junior army. No standardized playbook. What we build is configured to this asset, this founder, this launch.
Built for Emerging BioPharma. Not for everything.
Advisory and execution aren't separate engagements. We hold both threads from inside your team, not across a table from it. Strategy without execution is a document.
We think and execute, simultaneously.
Our scars are the product.
Friction-heavy launches. Strategies rebuilt mid-flight. Negotiations that went sideways. What you're hiring is the judgment that came out of that, and it doesn't come any other way.
Instinct
Some of it went well. Some of it did not. Both are why we know what we know.
20+
Full-cycle launches. Pre-NDA through post-launch. The whole arc, every time.
25+
Acquisition, integration, and restructuring programs led from inside the commercial function. Not managed from a distance.
75+
Combined years specifically at the pre-commercial and founder-led stage. Where there's no playbook and everything gets built for the first time.
125+
Combined years across our core members, inside commercial functions where the decisions actually landed.
WHERE WE SHOW UP.
Every engagement starts with a situation.
We don't sell services. We meet you where the pressure is.
Threat &
New Entry
Competitive Entry
Defense without a plan is just a slower loss.
Coverage Loss / Crisis
Access disappears in weeks. Getting it back takes quarters.
Performance & Change
Transformation
The model that got you here is now the thing in your way.
Performance Plateau
The numbers are flat. The answer isn't.
Launch & Growth
First Commercial Launch
Every assumption gets tested at once. Launch fails at the seams between functions, not inside them.
Post-Launch Scaling
What got you to launch will not get you through growth.
Pre Market
Pre Launch Readiness
The infrastructure gap always reveals itself at the worst possible moment.
Indication Expansion
The evidence exists. The commercial architecture to carry the added weight does not.
WHAT WE DO.
Commercial capabilities built to remove obstacles.
We work in the space between your team and the ecosystem around it. Evidence to access. Access to execution. The handoffs are where launches break.
Commercial Operations
The infrastructure that turns strategy into revenue.
Built to execute: stood up at the speed your stage demands.
-
Field force deployment and redesign
-
Field force effectiveness (FFE)
-
CSO strategy, design, and optimization
-
Turning performance data into revenue decisions
-
Converting formulary wins into scripts
Market Access
Without access, every other action fails to reach its potential.
Built for the market you're actually entering, not the one that looked good in the forecast.
-
Market Access & Trade Landscape Analyses and Strategy
-
Formulary access positioning and contracting
-
SP network optimization & contracting
-
MA & Trade integration with streamlined Patient Support Services
-
Prior auth pull-through strategy
-
Step therapy navigation and prescriber support
Clinical to Commercial
Clinical strategy is commercial strategy.
Built to close the gap between what the FDA approved and what the payer will cover.
-
Indication-specific value proposition and payer narrative
-
Evidence gap analysis for the new population
-
Label expansion and prescriber education strategy
-
Payer sequencing for new indication launch
-
Lifecycle positioning
OUR COMMERCIAL PHILOSOPHY.
The functions that determine outcome must be right first.
Commercial success is determined by what the label allows, what payers will cover, and what execution can convert. Every activity that follows builds on this foundation.
The Commercial Architecture
PERFORMANCE INTELLIGENCE
Measures and Refines
-
Analytics
-
Data Infrastructure
-
Competitive Intelligence
-
Finance
OPERATIONS INTEGRITY
Sustains and Protects
-
Legal
-
Compliance
-
Regulatory Affairs
-
HEOR post-approval
-
Access Vigilance
VOICE
Projects and Accelerates the Opportunity
-
Marketing
-
Brand
-
NPP
-
Digital
-
Medical Communications
-
Patient Engagement
THE COMMERCIAL ENGINE
Determines what is Commercially Achievable
-
Clinical to Commercial
-
Market Access
-
Commercial Operations
SCIENCE
Generates the Opportunity
-
R&D
-
Clinical Development
-
Medical Affairs
-
HEOR
-
Pharmacovigilance
What the label allows, what payers will cover, and what execution can convert. Everything else works inside those limits.
The label, access, and execution set the ceiling.
The label, the coverage, the conversion infrastructure. Those three decide the size of the opportunity before a single dollar goes to promotion. Every function downstream operates inside what they leave behind.
Nothing downstream saves you if that ceiling's wrong.
No amount of marketing closes a coverage gap the label created. A field team can't sell past a restriction. Support functions amplify what's there; they can't create what isn't.
Get the ceiling right, and everything else thrives.
Coverage unlocked. Label positioned. Execution infrastructure stood up. From there every other function multiplies instead of compensating.
HOW WE WORK.
Senior people. On the work.
From day one.
Senior people, on the work, from day one. Oriented in days.
No methodology deck or canned check lists standing between you and progress.
We work as part of your team.
Same accountability, same standard, same skin in the game. The tools and partners already in the room stay in the room.
We start with your situation.
The diagnosis comes before the prescription, every time.
We move at the speed your stage demands.
Pre-commercial means every week is load-bearing. Decisive with incomplete information, because that is the only kind available at this stage.
We stay through the inflection points.
Until the work holds without us in the room.
THE TEAM.
Depth earned.
Not claimed.
Every engagement is led by a senior practitioner who has carried what you're carrying.
The same people in the room at month six. No handoffs to a team you haven't met.
Paul Bragoli
Managing Partner
Market Access
He has spent his career inside the payer conversation. Across PBMs, national and regional plans, and the formulary committees that decide whether a therapy gets covered, gets restricted, or gets buried. He knows what moves payers, what stalls them, and where the leverage actually sits. That distinction is the whole job.
Craig Salmon-Gilmore
Commercial Effectiveness & Field Operations
He knows the difference between a formulary win and formulary pull-through. One is on paper. The other is what the field does every day after the access decision is made. That gap is where commercial performance either holds or quietly falls apart. Closing it is the work.
Andrew Joslyn
Trade, Distribution, & Channel Strategy
Thirty-one years of commercial pharma experience. Specialty pharmacy, trade, distribution, and the contracted relationships that determine whether a therapy actually reaches the patient. He has built the networks from scratch and run them at scale. The channel is where most launches quietly succeed or quietly fail.
Veron Browne, PhD
Clinical to Commercial
Translational & Clinical Strategy
Most organizations treat the transition from R&D to regulatory and commercial as a handoff. Veron treats it as the most consequential moment in the asset's life. Translational science, clinical strategy, and the evidence architecture that determines whether the molecule survives the gap between approval and access. PhD in Pharmacology and Toxicology. Founder of Alenvo, purpose-built regulatory intelligence for biotech and pharma.
Meghan Rivera
Executive Advisor
Commercialization Strategy
Early-stage companies don't fail on science alone. They fail when the path from approval to adoption isn't built. She shapes that path: commercial strategy, investor narrative, and the operating model required to turn an asset into a business.
W.H. Alvin Mok
Managing Partner
Transformation & Commercial Operations
The commercial infrastructure that determines whether a therapy reaches patients doesn't build itself. He builds it from the ground up for pre-commercial and emerging biopharma, where the first wrong decision determines the next eighteen months. The depth comes from having seen those same decisions play out at global scale.
ASH
December 5 to December 8 | San Diego, CA
Boston Biotech Week
September 22 to September 25 | Boston, MA
CONNECT WITH US.
We're at the following events. Let's talk!
THE DIFFERENCE IS HOW WE SHOW UP:
Not a document and a departure. The same people, in the room, until the work holds.
